Rankings
▼
Calendar
VRCA
Verrica Pharmaceuticals Inc.
$56M
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$8M
+47.7% YoY
Gross Profit
$5M
63.8% margin
Operating Income
-$66M
-871.3% margin
Net Income
-$77M
-1012.1% margin
EPS (Diluted)
$-14.78
Cash Flow
Operating Cash Flow
-$61M
Free Cash Flow
-$61M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$54M
Total Liabilities
$64M
Stockholders' Equity
-$10M
Cash & Equivalents
$46M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$8M
$5M
+47.7%
Gross Profit
$5M
$4M
+10.2%
Operating Income
-$66M
-$66M
-0.2%
Net Income
-$77M
-$67M
-14.3%
← Q4 2023
All Quarters
Q1 2024 →
VRCA FY 2024 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena